Hence, SAMHD1 could complement MSI/MMR status as a molecular marker involved in the high-risk definition for patients with stage II colorectal cancer and help in making clinical decisions for adjuvant chemotherapy for patients with stages II and III colorectal cancer. Here, SAMHD1 is linked to colorectal cancer.